Board of Directors

 

Pankaj Mohan, Ph.D.

Chairman, CEO & President


Dr. Mohan has served as our President, Chief Executive Officer and as Chairman and a member of our board of directors since January 2011. Prior to founding our company, from May 2008 to December 2010, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company. From June 2006 to May 2008, Dr. Mohan served as a Director of Bioprocess Engineering at Genentech, Inc., a biotechnology company. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom. From August 1987 to December 1989, Dr. Mohan served as a Scientific Officer for the Department of Atomic Energy for the Government of India.

Dr. Mohan has served as Chairman and as a member of the board of directors of Sonnet Biotherapeutics, Inc. since its inception in April 2015.

Dr. Mohan received a Ph.D. in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a masters in Financial Management from Middlesex University Business School, London, United Kingdom, an Executive Management Program (AMP) from Fuqua School of Business at Duke University and a Bachelor of Chemical Engineering from the Indian Institute of Technology in Roorkee, India.

 

Claudio Albrecht, Ph.D.

Dr. Albrecht has served as a member of our board of directors since October 2017. He is the Chairman of the Executive Board & Chief Executive Officer at STADA. Previously, he was co-founder and managing partner of Albrecht, Prock & Partners, which he created in 2013.  Dr. Albrecht served as the Chief Executive Officer of Actavis Group (2010-2012) and served as a Member of the Executive Board. He served as Chairman and Member of the Management Board at Ratiopharm Group and also served as its Chief Executive Officer from 2000 to 2005.

From 1987 to 2000, Dr. Albrecht served in senior management positions for Sandoz Pharmaceuticals AG, Switzerland, including as a Managing Director/General Manager of its generics business in the Netherlands, Germany and USA. He started his career with Sandoz in 1987. 

 

Scott Canute

Mr. Canute has served as a member of our board of directors since October 2011. From March 2010 to July 2011, Mr. Canute served as the President of Global Manufacturing and Corporate Operations of Genzyme Corporation. Prior to that, from 1982 to 2007, Mr. Canute served in various management positions at Eli Lilly and Company, including as the President of Global Manufacturing Operations, Vice President of Global Manufacturing, Vice President of Global Pharmaceutical Manufacturing and General Manager of European Manufacturing Operations. Mr. Canute also serves as a member of the technical advisory board of Moderna Therapeutics, Inc., and as a member of the board of directors of Proteon Therapeutics, Inc. and Flexion Therapeutics, Inc. In addition, Mr. Canute formerly served as a member of the board of directors of Inspiration Biopharmaceuticals, Inc. and AlloCure Inc.

Mr. Canute received an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from the University of Michigan.

 

Yezan Haddadin

Mr. Haddadin has served as a member of our board of directors since October 2017. He joined GMS Holdings in 2017 and leads the company's direct private equity investment platform focused on non-MENA markets, with an emphasis on North America. Yezan has over 17 years of investment banking and private equity experience. He has extensive experience across a range of industries and has advised on over USD 100 billion in M&A transactions in North America, Latin America, Europe, the Middle East and Africa.

Prior to joining GMS Holdings, Yezan was the Chief Executive Officer and Board Member of a regional investment bank based in Amman and Dubai (2014-2017); Advisor at Ripplewood Holdings LLC, a New York-based private equity firm (2013-2014); Managing Director at Perella Weinberg Partners in New York (2007-2013) and an Executive Director in JPMorgan's M&A Group in New York (2000-2007). He is currently a member of the Board of Directors at Sixth of October Investment Company ("SODIC"), a publicly listed Egyptian real estate development company and also a Board Member of The Near East Foundation, a New York- based private nonprofit development agency with projects in Africa and the Middle East.

Yezan holds a Juris Doctor from Northwestern University School of Law and a Bachelor of Science from Georgetown's School of Foreign Service. He is admitted to the New York State Bar Association and is an FAA licensed pilot.

 

Kurt J. Hilzinger

Mr. Hilzinger has served as a member of our board of directors since December 2015. He has extensive experience with companies that manage the supply of pharmaceuticals. He spent 16 years in various executive management capacities with AmerisourceBergen Corporation, serving as president and chief operating officer and earlier as executive vice president and chief financial officer. In 2007, he became a partner at Court Square Capital Partners, a private equity firm. Since 2003, Mr. Hilzinger has been on the board of managed care company, Humana, including serving as lead director from 2010 to 2014 when he became chairman of the Board. He serves on the Visiting Committee at the Ross School of Business at the University of Michigan, and also formerly served as Chairman of the Healthcare Distribution Management Association (HDMA), the trade association of the pharmaceutical distribution industry.

Mr. Hilzinger received his B.B.A. degree from the University of Michigan and is a Certified Public Accountant.

 

Faisal G. Sukhtian

Mr. Sukhtian has served as a member of our Board since September 2017. Mr. Sukhtian has served as a Director of GMS Tenshi Holdings Pte. Limited since 2011, and an Executive Director of GMS Holdings, a diversified investment company, since 2008. In addition to managing operations of GMS Holdings,Mr. Sukhtian oversees a number of investments within the GMS Holdings portfolio and serves as a director of GMS Holdings’ board of directors. From 2008 to 2011, Mr. Sukhtian served as Executive Director of Munir Sukhtian International. From 2010 to 2011, he served as Managing Director of Agri Sciences Ltd., an agrochemicals manufacturing business based in Turkey. Mr. Sukhtian has served as a member of the board of directors of Expert Petroleum, an oilfield services company based in Romania, since 2008, Agri Sciences since 2010, MS Pharma, a leading MENA based branded pharmaceutical generics company, since 2011 and Stelis Biopharma Private Limited, a biotherapeutic and biosimilar developer and manufacturer based in India, since 2015. Mr. Sukhtian previously served as a member of the board ofdirectors of Alvogen, a multinational generics pharmaceutical company based in the United States, from 2008 to 2014 and Waterloo Industries, Inc., a manufacturer of tool storage based in the United States, from 2015 to 2017. Prior to joining GMS Holdings, Mr. Sukhtian worked at JP Morgan, in New York, where he worked primarily on mergers and acquisitions, debt and equity transactions serving clients in the industrials and transportation industries.

Mr. Sukhtian received an M.B.A. from Columbia Business School and a B.S. in International Economics from Georgetown University’s School of Foreign Service. Mr. Sukhtian was appointed to fill a vacancy on the Board, and was designated for such vacancy by GMS Tenshi Holdings Pte. Limited pursuant to the Investor Rights Agreement by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited dated September 11, 2017.

 

Joe Thomas

Mr. Thomas has served as a member of our Board since September 2017. Since April 2015, Mr. Thomas has served as the Chief Executive Officer and Executive Director of Stelis Biopharma Private Limited, a biotherapeutic and biosimilar developer and manufacturer based in India, and is responsible for managing an integrated organization comprising research and development, manufacturing and commercialization of recombinant biotherapeutics in global markets. From January 2012 until March 2015, Mr. Thomas served as Chief Corporate Development Officer for Strides Shasun Limited, a listed pharmaceutical company based in India, and was responsible for development and deployment of growth strategies across group companies and business of Strides Shasun Limited. 

Mr. Thomas received both a B.Sc and M.Sc. in Chemistry from Delhi University and has over 30 years of experience in the pharmaceutical and consumer healthcare industry. Mr. Thomas was appointed to fill a vacancy on the Board, and was designated for such vacancy by GMS Tenshi Holdings Pte. Limited pursuant to the Investor Rights Agreement by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited dated September 11, 2017.

 


 

Board Observers and Advisors:

 

Nailesh Bhatt
Advisor, Commercialization

Mr. Bhatt is the Managing Director of Proximare and is assisting Oncobiologics in development of a US sales and marketing strategy which includes the identification and interactions between (i) payors, (ii) providers, (iii) pharmacy benefit management organizations, (iv) patients and (v) physicians.